A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

NCT04720716 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: IBI310
DRUG: Sintilimab
DRUG: Sorafenib

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.